Sector
PharmaceuticalsOpen
₹1,480Prev. Close
₹1,502.8Turnover(Lac.)
₹13,160.18Day's High
₹1,510.5Day's Low
₹1,48052 Week's High
₹1,702.0552 Week's Low
₹1,335Book Value
₹410.2Face Value
₹2Mkt Cap (₹ Cr.)
1,21,573.55P/E
24.69EPS
60.98Divi. Yield
1.0610 May 2024
12:00 AM
AGM
Announcement Date: 10 May, 2024
7 Apr 2025
12:00 AM
Board Meeting
Agenda : Audited Result
At the end of the inspection, the US FDA issued a Form 483 with one observation which was received at the conclusion of the inspection during the closing meeting.
The EBITDA margin saw a considerable improvement, moving up 184 basis points to 22.84%, from 21% in Q4 FY23.
For the quarter, net profit soared 49% on-year to ₹1,570 crore, on the back of higher revenue and better operating efficiency.
According to Cipla, the regulatory clearance serves as an important landmark in the Company's journey, allowing it to expand the depth of its oncology portfolio and its foothold in the US market
The VAI status indicates that there are no such complying issues with the facility; hence, the USFDA will not take any regulatory or administrative action against the facility.
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 161.47 | 161.43 | 161.36 | 161.29 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 27,812.45 | 24,476.66 | 22,352.19 | 19,766.27 |
Net Worth | 27,973.92 | 24,638.09 | 22,513.55 | 19,927.56 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 13,091.79 | 11,302.71 | 12,659.15 | 11,389.9 |
yoy growth (%) | 15.82 | -10.71 | 11.14 | 5.77 |
Raw materials | -5,090.24 | -4,103.61 | -4,319.21 | -4,155.49 |
As % of sales | 38.88 | 36.3 | 34.11 | 36.48 |
Employee costs | -1,729.16 | -1,703.58 | -1,911.08 | -1,785.94 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 3,546.23 | 2,784 | 2,964.31 | 1,988.92 |
Depreciation | -460.01 | -468.62 | -599.78 | -529.61 |
Tax paid | -856.84 | -739.35 | -646.14 | -442.88 |
Working capital | 1,126.76 | -61.34 | 1,238.17 | 865.57 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.82 | -10.71 | 11.14 | 5.77 |
Op profit growth | 9.74 | 13.3 | 23.3 | 37.54 |
EBIT growth | 26.3 | -5.7 | 49.95 | 63.18 |
Net profit growth | 19.83 | 6.47 | 57.85 | 50.62 |
| Particulars (Rupees in Crores.) | Mar-2025 | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|---|
Gross Sales | 27,145.4 | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 27,145.4 | 25,446.63 | 22,473.18 | 21,623.36 | 18,988.52 |
Other Operating Income | 402.22 | 327.46 | 279.94 | 139.98 | 171.07 |
Other Income | 861.87 | 746.57 | 475.45 | 280.91 | 265.99 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,687.4 | 94.51 | 4,04,767.81 | 2,000.46 | 0.95 | 7,107.14 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,725 | 80.79 | 1,78,467.89 | 667 | 0.45 | 2,536 | 561.08 |
Cipla Ltd CIPLA | 1,502.8 | 24.63 | 1,21,323.17 | 1,485.4 | 1.07 | 4,254.47 | 397.42 |
Dr Reddys Laboratories Ltd DRREDDY | 1,362.7 | 21.27 | 1,13,756.67 | 1,200.7 | 0.59 | 5,546.3 | 345.79 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,258.8 | 57.91 | 1,10,340.1 | 474 | 0.98 | 2,385 | 224.33 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Y K Hamied
Vice Chairman
M K Hamied
Non-Exec. & Independent Dir.
Adil Zainulbhai
Managing Director & Global CEO
Umang Vohra
Company Sec. & Compli. Officer
Rajendra Chopra
Independent Director
Robert A Stewart
Independent Director
P R Ramesh
Independent Director
Mandar Purushottam Vaidya
Non Executive Director
Samina Hamied
Additional Director
Abhijit A Joshi
Non Executive Director
Kamil Hamied
Independent Director
Sharmila Paranjpe
Independent Director
Maya Hari
Cipla House Peninsula Buss Par,
Ganpatrao Kadam Mg Lower Parel,
Maharashtra - 400013
Tel: 91-22-24826000
Website: http://www.cipla.com
Email: cosecretary@cipla.com, contactus@cipla.com
Karvy Selenium Tow-B,
31&32 Financial Dist, Nanakramguda,
Hyderabad-500032
Tel: 91-40-67162222
Website: www.kfintech.com
Email: einward.ris@kfintech.com
Summary
Cipla Limited is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Act...
Read More
Reports by Cipla Ltd
What is the Cipla Ltd share price today?
What is the Market Cap of Cipla Ltd?
What is the PE and PB ratio of Cipla Ltd?
What is the 52 Week High and Low of Cipla Ltd?
What is the CAGR of Cipla Ltd?
What is the shareholding pattern of Cipla Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
